< Back to Presentations
November 2024

Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B cells in Preclinical Models of Autoimmune Disease

ACR Convergence 2024 — November 14-19, 2024

Read More